High-Risk Beta
This platform is experimental. Smart contracts are unaudited. Use at your own risk.
r/science focuses on wegovy and times, with context pulled from source reporting instead of recycled feed copy.
What happened: Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of ‘eye stroke’ (ischaemic optic neuropathy) and sudden sight loss of the semaglutide drugs,... The risk is almost 5 times higher with Wegovy than it is with Ozempic, and 3 times greater...
What to watch next: movement around wegovy, times.
Potential exposure across 1 topic detected via keyword analysis.
Topic "ai" detected in article text via keyword matching.
Verbatim descriptions from source feeds — unedited, as received
r/science(lean-left)
Wegovy may have highest ‘eye stroke’ and sight loss risk of semaglutide GLP-1 agonists. The risk is almost 5 times higher with Wegovy than it is with Ozempic, and 3 times greater in men than it is in women.
Read full original ›MarketWatch(center)
This experimental pill helped people lose about 16% of their body weight after about a year of treatment
Read full original ›MarketWatch(center)
If middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound.
Read full original ›2 sources · 3 evidence links
Swarm Claim
Wegovy may have highest ‘eye stroke’ and sight loss risk of semaglutide GLP-1 agonists. The risk is almost 5 times higher with Wegovy than it is with Ozempic, and 3 times greater in men than it is in women.
r/science · link
Wegovy may have highest ‘eye stroke’ and sight loss risk of semaglutide GLP-1 agonists. The risk is almost 5 times higher with Wegovy than it is with Ozempic, and 3 times greater in men than it is in women.Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of ‘eye stroke’ (ischaemic optic neuropathy) and sudden sight loss of the semaglutide drugs,... The risk is almost 5 times higher with Wegovy than it is with Ozempic, and 3 times greater...
MarketWatch · link
This biotech is working on a GLP-1 pill that could be better than the Wegovy versionThis experimental pill helped people lose about 16% of their body weight after about a year of treatment
MarketWatch · link
Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound’s cash salesIf middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound.
This experimental pill helped people lose about 16% of their body weight after about a year of treatment
If middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound.
2 archived stories related to this coverage
This experimental pill helped people lose about 16% of their body weight after about a year of treatment
Business · archivedIf middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound.
Business · archivedConnect your wallet to join the discussion.
No comments yet. Be the first to share your take.